Formycon, Zydus Sign Exclusive Deal for Keytruda Biosimilar in US, Canada

10:35 AM EST, 12/09/2025 (MT Newswires) -- Formycon (FYB.F) signed an exclusive agreement with Zydus Lifesciences for the license and supply of its Keytruda biosimilar, FYB206, across the US and Canada, according to a Tuesday release. As agreed, the German biosimilar company will handle development, filing of the regulatory dossier, and product supply. In return, it will receive upfront and milestone payments in 2025 in the mid-teens-million-euro range, along with additional payments tied to defined development and regulatory milestones, as well as a share of gross profits. Zydus, meanwhile, will manage commercialization in the US and Canada.